Efficacy and safety of oral ibrexafungerp in Chinese patients with vulvovaginal candidiasis: a phase III, randomized, double-blind study

安慰剂 医学 内科学 氟康唑 临床终点 不利影响 外阴阴道念珠菌病 白色念珠菌 临床试验 随机对照试验 胃肠病学 皮肤病科 抗真菌 替代医学 病理 生物 遗传学
作者
Xiaoqian Wang,Wenying Wang,Jing Wang,Ruifang An,Lihong Chen,Jiajing Lin,Dabao Xu,Jin Qiu,Weihua Song,Mijiti Patiman,Hongjie Ruan,Gang Wang,Fengxia Xue,Sheng Wang,Xiaowan Luo,Qiuqi Ruan,Ling Shi,Chun Zhang,Lina Hu,Shijin Wang,S-H Hong,Zhenjun Li,Songling Zhang,Yingxiong Li,Jing Lu,Bao-jin Wang,Hongyan Xu,Ye Hong,Bei Zhang,Chunlian Zhang,Sumin Qian,Qiong Wu,Jia Wen,Chuan Li,Qinping Liao
出处
期刊:Infection [Springer Science+Business Media]
标识
DOI:10.1007/s15010-024-02233-w
摘要

Abstract Purpose To evaluate the efficacy and safety of oral ibrexafungerp (HS-10366) versus placebo in Chinese patients with vulvovaginal candidiasis (VVC). Methods A double-blind, placebo-controlled, randomized, multicenter phase III study was conducted in symptomatic VVC patients. Patients received (2:1) twice-daily oral ibrexafungerp 300 mg or matching placebo for 1 day. The primary endpoint was clinical cure (vulvovaginal signs and symptoms [VSS] score = 0) at test-of-cure (TOC) on day 11 ± 3. The secondary endpoints included mycological eradication, overall response, and clinical improvement (VSS score ≤ 1) at TOC, and vulvovaginal symptom resolution at follow-up on day 25 ± 4. Results In total, 360 patients were included in the modified intention-to-treat set (defined as positive Candida cultured and receiving at least one study drug; 239 for ibrexafungerp, 121 for placebo). Compared with placebo, patients receiving ibrexafungerp had a significantly higher proportion of clinical cure (51.0% vs. 25.6%), mycological eradication (55.6% vs. 18.2%), overall response (33.9%, vs. 8.3%) at TOC and complete symptom resolution (74.5% vs. 39.7%, all P < 0.001) at follow-up. Subgroup analysis of clinical cure indicated that patients with C. albicans could benefit from ibrexafungerp over placebo. A similar benefit trend was also observed in those with non- albicans Candida by post-hoc analysis. Further analyses revealed similar efficacy of ibrexafungerp between patients with fluconazole non-susceptible C. albicans and fluconazole susceptible C. albicans regarding clinical cure and mycological eradication. Ibrexafungerp was generally well tolerated. Adverse events were primarily gastrointestinal and were mainly mild in severity. Conclusions As a first-in-class antifungal agent, ibrexafungerp demonstrated promising efficacy and favorable safety for VVC treatment in Chinese patients. Chinadrugtrials.org.cn registry number CTR20220918.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
彭理理发布了新的文献求助10
2秒前
科研通AI2S应助氧泡泡采纳,获得10
2秒前
zhouzhou发布了新的文献求助10
3秒前
4秒前
李健应助yzheh采纳,获得10
5秒前
5秒前
李冬卿完成签到,获得积分10
6秒前
6秒前
英吉利25发布了新的文献求助10
7秒前
8秒前
Elaine完成签到,获得积分10
9秒前
9秒前
司宁完成签到,获得积分10
10秒前
小马甲应助小佟采纳,获得10
10秒前
顺心的满天完成签到,获得积分10
11秒前
SciGPT应助柔弱的问梅采纳,获得10
11秒前
12秒前
13秒前
wjx发布了新的文献求助10
13秒前
传奇3应助芒果布丁采纳,获得10
13秒前
14秒前
XX完成签到,获得积分10
14秒前
量子星尘发布了新的文献求助10
15秒前
研友_LjDyNZ发布了新的文献求助10
15秒前
16秒前
梧桐发布了新的文献求助10
16秒前
16秒前
17秒前
17秒前
大帅发布了新的文献求助10
18秒前
星辰大海应助dudu采纳,获得10
19秒前
westbobo完成签到,获得积分10
19秒前
寸愿发布了新的文献求助10
19秒前
cj完成签到,获得积分10
19秒前
dsf发布了新的文献求助20
20秒前
20秒前
21秒前
whitedawn发布了新的文献求助10
21秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974882
求助须知:如何正确求助?哪些是违规求助? 3519431
关于积分的说明 11198315
捐赠科研通 3255698
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877237
科研通“疑难数据库(出版商)”最低求助积分说明 806219